Twist Bioscience Corporation (NASDAQ:TWST) CEO Sells $17,226.44 in Stock

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 476 shares of the company's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $36.19, for a total value of $17,226.44. Following the transaction, the chief executive officer directly owned 645,306 shares in the company, valued at $23,353,624.14. This trade represents a 0.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Twist Bioscience Stock Up 2.9%

Shares of NASDAQ:TWST traded up $1.04 during midday trading on Tuesday, reaching $36.63. 301,453 shares of the company were exchanged, compared to its average volume of 964,931. Twist Bioscience Corporation has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $33.40 and a two-hundred day simple moving average of $40.08. The firm has a market cap of $2.19 billion, a PE ratio of -11.30 and a beta of 2.41.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. The firm had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on TWST shares. Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. The Goldman Sachs Group cut their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Barclays cut their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $50.40.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC increased its position in shares of Twist Bioscience by 11.5% in the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after acquiring an additional 645,730 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Twist Bioscience by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after purchasing an additional 60,276 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Twist Bioscience by 186.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after purchasing an additional 1,588,587 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after buying an additional 532,040 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock worth $63,895,000 after buying an additional 6,908 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.